Progress Report on the Hypertension Objective Treatment Based on Measurement by Electrical Devices of Blood Pressure (HOMED-BP) Study: Status at February 2004

• Published in: Clinical and experimental hypertension (1993) 2007, Vol.29 (1), p.69-81
• Main Authors: Hosohata, Keiko, Saito, Shin, Asayama, Kei, Ohkubo, Takayoshi, Kikuya, Masahiro, Metoki, Hirohito, Obara, Taku, Kato, Tetsuo, Hashimoto, Junichiro, Totsune, Kazuhito, Miura, Yukio, Imai, Yutaka
• Format: Article
• Language: English
• Subjects: Aged; Angiotensin II Type 1 Receptor Blockers - pharmacology; Angiotensin II Type 1 Receptor Blockers - therapeutic use; Angiotensin-Converting Enzyme Inhibitors - pharmacology; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Blood Pressure - drug effects; Blood Pressure - physiology; blood pressure measurement at home; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers - pharmacology; Calcium Channel Blockers - therapeutic use; Dose-Response Relationship, Drug; Female; Humans; hypertension; Hypertension - drug therapy; Hypertension - physiopathology; Internet; Japan; Male; Middle Aged; prospective randomized open-label blinded-endpoint (PROBE); randomized controlled trial (RCT); Research Design; Time Factors
• ISSN: 1064-1963; 1525-6006
• DOI: 10.1080/10641960601096976

The Hypertension Objective Treatment Based on Measurement by Electrical Devices of Blood Pressure (HOMED-BP) Study is the first large-scale intervention trial in Japan using a PROBE design to determine an optimal target blood pressure (BP) level on the basis of self-measured BP at home and optimal initial antihypertensive medication. The registered patients are randomized to one of two different BP levels and to initial antihypertensive regimens (i.e., calcium antagonist [Ca-A], angiotensin-converting enzyme inhibitor [ACE-I], or angiotensin II receptor antagonist [ARB]). At the end of February 2004, 2729, 1687, and 971 patients were recruited, randomized, and followed-up for 12 months or more. Among the 971 patients, mean systolic/diastolic BP levels at randomization in the Ca-A, ACE-I, and ARB groups were 150/90, 152/89, and 151/89 mmHg, respectively. These values reduced after six months of Ca-A-, ACE-I-, and ARB-based treatment (133/81 mmHg, 135/80 mmHg, and 134/79 mmHg, respectively) and further reduced after 12 months (131/80 mmHg, 134/79 mmHg, and 132/79 mmHg, respectively) without any significant differences among groups. In more intensive and less intensive BP-lowering groups, mean systolic/diastolic BP levels at randomization were 151/90 and 150/89 mmHg, respectively. Although BP levels reduced after 6-month (135/80 mmHg and 133/80 mmHg, respectively) and 12-month treatment (133/79 mmHg and 132/80 mmHg, respectively) in each target group, no significant difference in BP values was observed between groups. These results indicate the necessity of additional interventional strategies to improve the achievement of target BP levels, especially in the more intensive BP-lowering group.